- Stocks
- Pharma & Healthcare
- Gujarat Themis Biosyn
Gujarat Themis Biosyn share price
NSE: GUJTHEMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Gujarat Themis Biosyn at a glance
Gujarat Themis Biosyn (NSE: GUJTHEM) closed at ₹365.70 on 22 Oct 2026, up 4.88% on the day. With a market capitalisation of ₹3,985 Cr, it ranks 876th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 85.4× trailing earnings, against a return on equity of 19.6% in FY25. Over the past year the share price has fallen 11.9%. Its 52-week range is ₹225.05 (30 Mar 2026) to ₹479.00 (27 Oct 2025); the last close is 23.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹44 Cr (+17.2% year on year) and net profit ₹11 Cr (−9.3%), on a standalone basis. Promoters held 70.86% of the company as of 30 Jun 2026; 68.49% of promoter shares were pledged.
Key numbers
- Market cap
- ₹3,985 CrRank 876 on NSE
- P/E (trailing)
- 85.4×
- Price to book
- 12.35×FY25
- EPS (TTM)
- ₹4.28to Q4 FY26
- ROE
- 19.6%FY25
- ROCE
- 23.5%FY25
- Debt to equity
- 0.12FY25
- Net profit margin
- 32.3%FY25
- Book value / share
- ₹22.79FY25
- Dividend payout
- 3.7%FY25
- 52-week high
- ₹479.0027 Oct 2025
- 52-week low
- ₹225.0530 Mar 2026
- 1-year return
- −11.9%
- RSI (14-day)
- 43.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +4.88% | −4.5% | −11.3% | +4.5% | −11.9% |
Gujarat Themis Biosyn quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹39 Cr | ₹35 Cr | ₹40 Cr | ₹38 Cr | ₹36 Cr | ₹42 Cr | ₹43 Cr | ₹44 Cr |
| Revenue YoY | −21.7% | −12.4% | +1.7% | −10.2% | −7.6% | +22.0% | +9.7% | +17.2% |
| Net profit | ₹13 Cr | ₹11 Cr | ₹13 Cr | ₹12 Cr | ₹9 Cr | ₹14 Cr | ₹12 Cr | ₹11 Cr |
| Net profit YoY | −25.3% | −15.7% | −0.3% | −24.5% | −31.6% | +34.9% | −3.9% | −9.3% |
| Net margin | 34.1% | 30.4% | 32.8% | 31.8% | 25.3% | 33.7% | 28.7% | 24.6% |
| EPS | ₹1.82 | ₹0.97 | ₹1.19 | ₹1.10 | ₹0.83 | ₹1.31 | ₹1.14 | ₹1.00 |
Gujarat Themis Biosyn financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹85 Cr | ₹91 Cr | ₹115 Cr | ₹149 Cr | ₹170 Cr | ₹151 Cr |
| Operating profit | ₹31 Cr | ₹41 Cr | ₹59 Cr | ₹77 Cr | ₹79 Cr | ₹66 Cr |
| Net profit | ₹24 Cr | ₹30 Cr | ₹44 Cr | ₹58 Cr | ₹59 Cr | ₹49 Cr |
| EPS (₹) | ₹16.30 | ₹20.77 | ₹30.03 | ₹39.90 | ₹8.14 | ₹4.48 |
| Cash from operations | ₹1 Cr | ₹6 Cr | ₹40 Cr | ₹40 Cr | ₹64 Cr | ₹91 Cr |
| Total debt | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹30 Cr |
| Shareholders' equity | ₹42 Cr | ₹70 Cr | ₹103 Cr | ₹149 Cr | ₹201 Cr | ₹248 Cr |
Gujarat Themis Biosyn shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 70.86% | 70.86% | 70.86% | 70.86% | 70.86% |
| Foreign institutions | 2.51% | 2.95% | 1.96% | 1.80% | 1.77% |
| Domestic institutions | 1.17% | 1.17% | 1.17% | 1.18% | 1.18% |
| Non-institutions | 25.45% | 25.01% | 26.00% | 26.16% | 26.19% |
| Promoter shares pledged | 3.30% | 3.30% | 4.49% | 5.44% | 68.49% |
Gujarat Themis Biosyn vs peers
The listed Pharma & Healthcare companies nearest to Gujarat Themis Biosyn by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NOVARTINDNovartis India | ₹1,810.70 | +2.71% | +224.4% | ₹4,471 Cr | 48 | — |
| ORCHPHARMAOrchid Pharma | ₹876.25 | +0.06% | +20.9% | ₹4,444 Cr | 214.2 | — |
| SMSPHARMASMS Pharmaceuticals | ₹434.55 | +0.59% | +59.0% | ₹4,070 Cr | 39 | — |
| GUFICBIOGufic Biosciences | ₹401.55 | +3.43% | +9.9% | ₹4,027 Cr | 62.7 | — |
| GUJTHEMGujarat Themis Biosyn | ₹365.70 | +4.88% | −11.9% | ₹3,985 Cr | 85.4 | — |
| UNICHEMLABUnichem Laboratories | ₹495.95 | −3.51% | +5.5% | ₹3,492 Cr | 13.8 | — |
| AARTIDRUGSAarti Drugs | ₹381.15 | −1.51% | −24.5% | ₹3,479 Cr | 17.9 | — |
Ask anything about Gujarat Themis Biosyn
Pivot answers on the live chart with evidence you can check, and tests strategies against GUJTHEM's own history. Try: “Why has GUJTHEM moved over the last three months?” · “Backtest a 50-day moving-average crossover on GUJTHEM over five years” · “Compare GUJTHEM with NOVARTIND on margins and valuation”
Frequently asked questions about Gujarat Themis Biosyn
What is the share price of Gujarat Themis Biosyn today?
Gujarat Themis Biosyn (NSE: GUJTHEM) last closed at ₹365.70 on 22 Oct 2026. Its 52-week high is ₹479.00 and its 52-week low is ₹225.05.
What is the market cap of Gujarat Themis Biosyn?
Gujarat Themis Biosyn's market capitalisation is ₹3,985 Cr (₹3,985 Cr) at the 22 Oct 2026 close, ranking 876th among the NSE companies Pivot tracks.
What is the P/E ratio of Gujarat Themis Biosyn?
Gujarat Themis Biosyn trades at a trailing P/E of 85.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.
What is the ROE and ROCE of Gujarat Themis Biosyn?
Return on equity was 19.6% in FY25 and return on capital employed was 23.5% in FY25 (standalone figures).
Is Gujarat Themis Biosyn a debt-free company?
No. Gujarat Themis Biosyn's debt-to-equity ratio was 0.12 in FY25, with total debt of ₹30 Cr.
What were Gujarat Themis Biosyn's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Gujarat Themis Biosyn reported revenue of ₹44 Cr, +17.2% year on year, and net profit of ₹11 Cr, −9.3% year on year.
How has Gujarat Themis Biosyn stock performed over the last year?
Gujarat Themis Biosyn's share price has fallen 11.9% over the past year, +4.5% over three months and −11.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Gujarat Themis Biosyn?
As of 30 Jun 2026: promoters 70.86%, foreign institutions 1.77%, domestic institutions 1.18%, non-institutions 26.19%. 68.49% of promoter shares were pledged.
Who are Gujarat Themis Biosyn's competitors?
The listed Pharma & Healthcare companies closest to Gujarat Themis Biosyn by market cap are Novartis India, Orchid Pharma, SMS Pharmaceuticals, Gufic Biosciences, Unichem Laboratories and Aarti Drugs.
Is Gujarat Themis Biosyn a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Gujarat Themis Biosyn's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GUJTHEM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text